In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...

Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...

In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down ...

Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down Sanofi’s latest partnerships aimed at advancing Alzheimer’s and autoimmune ...

In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...

Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...

New survey data show a strong patient preference for fully remote clinical trials, underscoring how convenience, intuitive technology, and FDA-cleared digital tools are reshaping enrollment and ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...